Myotonic muscular dystrophy is a genetic multisystem disease caused by a repeat expansion in one of two genes, and despite the name it is not primarily a muscle-membrane disease like Duchenne. The expanded repeat is transcribed into a toxic RNA that clumps inside the nucleus and derails the splicing of many other genes, which is why patients get myotonia, distal weakness, cataracts, cardiac conduction block and insulin resistance from a single mutation.
For readers who found this page from a myostatin angle, the honest headline is this: no myostatin inhibitor has ever been tested in myotonic dystrophy in a registered clinical trial. Not one. The drugs actually in late-stage development for this disease work on the RNA, not on the growth factor. That gap is worth understanding before anyone extrapolates muscle-building biology onto this condition.
What myotonic muscular dystrophy is
The clinical literature calls it myotonic dystrophy, and DM1 is also known as Steinert disease. "Myotonic muscular dystrophy" is the older lay term and still the way most people search for it.
Two features define it. Myotonia is delayed muscle relaxation after contraction, most recognisable as an inability to quickly release a hand grip. Dystrophy is the progressive wasting and weakening of muscle. Both come from the same mutation.
What separates it from most other dystrophies is how far the damage reaches beyond skeletal muscle. GeneReviews reports conduction defects in 90% of individuals with DM1, along with the characteristic "Christmas tree" cataracts visible on slit-lamp exam, hyperinsulinism, thyroid dysfunction and diabetes. The cardiac involvement is the part that most changes life expectancy, and it can appear before weakness is disabling.
DM1 and DM2 are different genes with different repeats
DM1 is caused by a CTG trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene on chromosome 19q13.32. GeneReviews classifies 5 to 34 repeats as normal, 35 to 49 as a mutable normal (premutation) allele, and more than 50 repeats as full-penetrance. Onset falls into three broad phenotypes: mild (20 to 70 years), classic (10 to 30 years) and congenital (birth to 10 years).
DM2 is caused by a CCTG expansion within a complex repeat tract in the CNBP gene on chromosome 3q21.3. Pathogenic expansions run from roughly 75 to more than 11,000 repeats, with a mean of about 5,000.
The clinical differences matter for anyone reading about muscle loss. DM1 affects both proximal and distal muscles, with the facial and hand muscles hit especially hard; the distal weakness produces foot drop and loss of fine manual dexterity. DM2 weakness is predominantly proximal and axial, the course is typically slower, and DM2 has no true congenital form.
DM1 shows anticipation: the repeat can expand during gametogenesis, so a longer allele is passed to the next generation and symptoms start earlier and hit harder. Anticipation is not confirmed in DM2. Both types are autosomal dominant, so a single altered copy is sufficient.
How common is it
Sources disagree, and it is worth naming that rather than picking the friendlier number.
MedlinePlus Genetics states that myotonic dystrophy "affects at least 1 in 8,000 people worldwide" and describes it as the most common form of muscular dystrophy that begins in adulthood. GeneReviews gives a narrower estimate for DM1 alone: prevalence ranging from 1:100,000 in some areas of Japan to 1:10,000 in Iceland, with an overall estimated worldwide prevalence of 1:20,000.
Those figures are differently scoped rather than contradictory. Founder effects create large regional variation, DM2 is under-diagnosed, and mild adult-onset cases go unrecognised for years. In Germany, DM2 prevalence has been estimated at roughly 9:100,000, about as common as DM1 there.
If you are looking for the administrative coding rather than the epidemiology, see our page on muscular dystrophy ICD-10 codes.
Why the muscle loss here is not ordinary atrophy
This is the part that gets flattened in most consumer content. The wasting in myotonic dystrophy is downstream of an RNA defect, not of a failure to build muscle protein.
A 2023 systematic review of protein phosphorylation in DM1 catalogued 29 kinases, 3 phosphatases and 17 phosphoproteins reported as altered, with disruption spanning AKT/mTOR, MEK/ERK, PKC/CUGBP1 and AMPK signalling. That is a broad derangement of the pathways controlling muscle growth, glucose handling and cell survival, driven upstream by the toxic repeat RNA.
The body composition consequences are measurable. A DEXA study of male DM1 patients found significantly higher fat mass index and significantly lower fat-free mass index and skeletal mass index than healthy volunteers, alongside a significantly lower resting energy expenditure that was not associated with body composition. In plain terms: less lean mass, more fat mass, and a metabolic rate that does not track with either. For general background on how muscle is lost in other settings, see muscle atrophy.
Where myostatin fits, and where the evidence stops
Myostatin is the endogenous brake on muscle growth, and blocking it enlarges muscle in healthy animals. The obvious hypothesis is that releasing that brake could offset wasting in a dystrophy. It has been tested in humans, but not in this disease.
The landmark trial was MYO-029 (stamulumab), a neutralising anti-myostatin antibody. Wagner and colleagues enrolled 116 adults across four dose-escalation cohorts (1, 3, 10 and 30 mg/kg) in a double-blind, placebo-controlled study published in Annals of Neurology in 2008. The enrolled populations were Becker muscular dystrophy, facioscapulohumeral dystrophy and limb-girdle muscular dystrophy. Myotonic dystrophy was not included.
The result was a safety trial, and the authors said so. MYO-029 had good safety and tolerability apart from cutaneous hypersensitivity at the 10 and 30 mg/kg doses. No improvements were seen in exploratory endpoints of muscle strength or function, though the study was not powered for efficacy, and there was a trend in a limited number of subjects toward increased muscle size on DEXA and histology. A companion analysis of single muscle fibers from six of those patients reported improved contractile properties in four of the five who received drug, which is a cellular signal in a very small sample, not a clinical outcome. More on this drug class at anti-myostatin antibody and on the trialed population at limb-girdle muscular dystrophy.
Searching ClinicalTrials.gov for myostatin, follistatin, activin, bimagrumab, apitegromab or taldefgrobep against a myotonic dystrophy condition returns zero studies. A PubMed search for myostatin and myotonic dystrophy returns two records, only one of which actually measures it.
That one study is worth reporting accurately. Pegoraro and colleagues followed nine genetically confirmed DM1 patients through 3 to 6 weeks of controlled aerobic rehabilitation. Six-minute walk distance increased by 53.5 m (p < 0.0004) and 10-metre walk time fell by 1.38 s. Serum myostatin, measured by ELISA, was significantly downregulated after training, in parallel with myomiRNAs miR-1, miR-206, miR-133a and miR-133b. Nine patients, no control arm, biomarker endpoints. The authors themselves called for further investigation.
So the state of play: myostatin is measurable and moves with exercise in DM1, and it has never been pharmacologically targeted here. Anyone claiming otherwise is extrapolating from Duchenne, where the record is better documented — see myostatin in Duchenne. For how myostatin is quantified at all, see myostatin blood test.
What is actually in the DM1 pipeline
The serious programmes target the toxic RNA rather than muscle growth signalling.
- Del-desiran (AOC 1001), an antibody-oligonucleotide conjugate from Avidity Biosciences, is in a Phase 3 randomised, quadruple-masked, placebo-controlled global study with 159 participants and hand function as the primary outcome. The registry lists a primary completion date of August 2026; as of this writing no results have been posted to the record.
- Zeleciment basivarsen (DYNE-101) from Dyne Therapeutics is in a Phase 3 trial in DM1, listed as recruiting with primary completion in July 2028.
- PGN-EDODM1 from PepGen is in a Phase 2 study.
- SRP-1003 from Sarepta is in a Phase 1/2a double-blind, placebo-controlled, dose-escalating study of single and multiple ascending doses, with a planned enrolment of 78.
Registration is not evidence of efficacy. These are the programmes that exist, at the stages the registry reports.
Symptom management today
There is no approved disease-modifying therapy for myotonic dystrophy. Management is symptomatic and surveillance-based, with cardiac monitoring carrying particular weight given the 90% figure for conduction defects.
Mexiletine is the best-studied drug for the myotonia itself, and the evidence is more nuanced than "it works." Two randomised crossover trials of 20 DM1 participants each, published in Neurology in 2010, tested 150 mg and 200 mg three times daily against placebo over 7-week periods and found significant reductions in grip relaxation time at both doses, without prolongation of PR, QRS or QTc. A later randomised, double-blind, placebo-controlled trial of 42 participants published in Neurology in 2021 found no benefit on 6-minute walk distance at 6 months, its primary endpoint, while hand grip myotonia did improve objectively — a change participants did not perceive themselves.
Those doses are what the trials administered, not a recommendation. Mexiletine is an antiarrhythmic being used in a population with a high baseline rate of conduction disease, and whether it is appropriate is a prescriber's decision made with cardiology input.
FAQ
Is myotonic muscular dystrophy the same as muscular dystrophy? It is one type within the muscular dystrophy family, and it is the most common form beginning in adulthood according to MedlinePlus Genetics. It differs from Duchenne and limb-girdle dystrophies in mechanism: those involve structural muscle proteins, while myotonic dystrophy is driven by a toxic repeat RNA that disrupts splicing across many genes.
Can myostatin inhibitors treat myotonic dystrophy? There is no clinical evidence that they can. No myostatin inhibitor has been tested in a registered trial in myotonic dystrophy. The one human trial of an anti-myostatin antibody in adult dystrophies, MYO-029, enrolled Becker, facioscapulohumeral and limb-girdle patients only, and reported no improvement in strength or function even in those groups.
What is the difference between DM1 and DM2? Different genes and different repeats: CTG in DMPK for DM1, CCTG in CNBP for DM2. DM1 involves distal as well as proximal muscles, shows anticipation across generations, and has a congenital form. DM2 weakness is mainly proximal and axial, tends to progress more slowly, and has no congenital form.
Does exercise help? The controlled evidence is thin but not absent. The nine-patient DM1 rehabilitation study found a 53.5 m improvement in 6-minute walk distance after 3 to 6 weeks of aerobic training, with serum myostatin falling in parallel. That is a small uncontrolled study, and exercise prescription in a disease with cardiac conduction risk needs medical supervision.
Is there a cure? No. Several RNA-targeted programmes have reached Phase 2 and Phase 3, but none has an approval, and the largest Phase 3 had not posted results at the time of writing. Current care manages myotonia, cardiac rhythm, respiratory function, cataracts, glucose handling and daytime sleepiness rather than the underlying expansion.